IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 117 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
   Next article
   Previous article 
   Table of Contents
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Article in PDF (98 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   References
   Article Figures

 Article Access Statistics
    Viewed4447    
    Printed63    
    Emailed3    
    PDF Downloaded138    
    Comments [Add]    
    Cited by others 17    

Recommend this journal

 


 
LETTER TO EDITOR
Year : 2005  |  Volume : 71  |  Issue : 4  |  Page : 287-288

Lichenoid eruption due to imatinib


Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India

Correspondence Address:
K Prabhash
B7/99, Sector -4, Rohini, New Delhi
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0378-6323.16627

Rights and Permissions



How to cite this article:
Prabhash K, Doval D C. Lichenoid eruption due to imatinib. Indian J Dermatol Venereol Leprol 2005;71:287-8

How to cite this URL:
Prabhash K, Doval D C. Lichenoid eruption due to imatinib. Indian J Dermatol Venereol Leprol [serial online] 2005 [cited 2019 Jun 26];71:287-8. Available from: http://www.ijdvl.com/text.asp?2005/71/4/287/16627


Sir,

Imatinib mesylate is a tyrosine kinase inhibitor. It inhibits tyrosine kinases of bcr-abl, c-Kit and platelet derived growth factor receptors (PDGFRs). This drug has revolutionized the treatment of chronic myeloid leukemia (CML) and has been recently approved as first line treatment in CML patients. Most patients receiving imatinib experience hematological and non-hematological side effects. The common non-hematological side effects are nausea, musculoskeletal pain, superficial edema, skin rashes and muscular cramps. Skin changes are the most common non-hematological adverse effects.[1] The prevalence and their relationship with the dose suggests that they are due to the direct pharmacological effect of imatinib.[2] There are three reports of a lichenoid skin eruption due to imatinib. [6],[7],[8]

A 50-year-old man presented with weakness and fatigue in November 2002. He had hepatomegaly of 4 cm and splenomegaly of 2 cm. Bone marrow aspiration was suggestive of chronic myeloproliferative disorder. Leukocyte alkaline phosphatase score was zero. His cytogenetic study was positive for Philadelphia chromosome positive. He received hydroxyurea and interferon 5 MIU/day, but there was no hematological remission and cytogenetically there was no response. He was started on imatinib 400 mg/day in May 2003. He achieved complete hematological response within two months. The cytogenetic response was partial at six months and complete at 12 months.

Six months after imatinib was started, he noticed hyper-pigmented skin lesions on the eyelids [Figure - 1], which slowly spread to involve the neck, chest, and limbs. The lesions were maculopapular, brownish black in color and non-pruritic. He refused a skin biopsy of the pigmented lesions. The patient was continued on imatinib and is doing well.

The common cutaneous adverse effects of imatinib are superficial skin edema, rashes, hypopigmentation and pruritus.[1] Rarely does it lead to severe epidermal necrolysis, acute generalized exanthematous pustulosis, hyperpigmentation or a lichenoid eruption.[3],[4],[5],[6] Reports of pigmentary changes due to imatinib are from ethnically pigmented patients, with 40.9% having hypopigmentation.[3] The molecular mechanism for the skin changes is not clear. In one report, all seven patients having depigmentation had a skin rash, suggesting a common etiology, but in another report, only 5.4% patients of patients with pigmentary changes had a skin rashe, indicating a complex molecular interaction.[2],[3]

Two of the three reported cases of lichenoid eruption due to imatinib had involvement of the buccal mucosa, and one had skin involvement. [6],[7],[8] The eruption started 12 weeks after imatinib was first administered in two patients, and after eight weeks in the third. Our patient developed a skin eruption six months after imatinib was started. This case illustrates that a lichenoid eruption can occur in patients receiving imatinib. The eruption may be mild or extensive. The mild form may not need discontinuation of imatinib as in our patients. If it is extensive, then temporary discontinuation might be needed.



 
  References Top

1.O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.  Back to cited text no. 1      
2.Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P, et al. Adverse cutaneous reactions to Imatinib (STI-571) in Philadelphia chromosome positive leukemias: A prospective study of 54 patients. J Am Acad Dermatol 2003;48:201-6.  Back to cited text no. 2      
3.Arora B, Kumar L, Sharma A, Wadhwa J, Kochupillai V. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. Ann Oncol 2004;15:358-9.   Back to cited text no. 3      
4.Schaich M, Schakel K, Illmer T, Ehninger G, Bornhauser M. Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplant. Ann Hematol 2003;82:303-4.  Back to cited text no. 4      
5.Schwarz M, Kreuzer KA, Baskaynak G, Dorken B, le Coutre P. Imatinib induces acute generalized exanthematous pustulosis in two patients with chronic myeloid leukemia. Eur J Haematol 2002;69:254-6.  Back to cited text no. 5      
6.Lim D, Muir J. Imatinib for chronic myeloid leukemia: a NICE mess. Lancet 2001;358:1903.  Back to cited text no. 6      
7.Lim D, Muir J. Oral lichenoid reaction to imatinib. Dermatology 2002;205:169-71  Back to cited text no. 7      
8.Roux C, Boisseau-Gersaud AM, Saint-Cyr I, Hekenon R, Quist D, Delaunay C. Lichenoid cutaneous reaction to imatinib. Ann Dermatol Venereol 2004;131:571-3.  Back to cited text no. 8      


    Figures

  [Figure - 1]

This article has been cited by
1 Lichen planus and other lichenoid dermatoses: Kids are not just little people
Michael J. Payette,Gillian Weston,Stephen Humphrey,JiaDe Yu,Kristen E. Holland
Clinics in Dermatology. 2015; 33(6): 631
[Pubmed] | [DOI]
2 Adverse Skin Effects of Imatinib, a Tyrosine Kinase Inhibitor
M. Pretel-Irazabal,A. Tuneu-Valls,N. Ormaechea-Pérez
Actas Dermo-Sifiliográficas (English Edition). 2014; 105(7): 655
[Pubmed] | [DOI]
3 Cross Skin Reactivity to Tyrosine Kinase Inhibitors in a Patient with Chronic Myelogenous Leukemia
V. Broshtilova,M. Balabanova
Journal of Cancer Therapy. 2013; 04(07): 1141
[Pubmed] | [DOI]
4 Lichenoid drug eruption with hyperpigmentation caused by imatinib mesylate
Yoshiko Kagimoto,Masato Mizuashi,Katsuko Kikuchi,Setsuya Aiba
International Journal of Dermatology. 2013; : n/a
[Pubmed] | [DOI]
5 Efectos adversos cutáneos del imatinib (inhibidor de la tirosín cinasa)
M. Pretel-Irazabal,A. Tuneu-Valls,N. Ormaechea-Pérez
Actas Dermo-Sifiliográficas. 2013;
[Pubmed] | [DOI]
6 Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience
V. Brazzelli,V. Grasso,G. Borroni
Journal of the European Academy of Dermatology and Venereology. 2013; : n/a
[Pubmed] | [DOI]
7 Advances in the Management of Cutaneous Toxicities of Targeted Therapies
Caroline Robert,Vincent Sibaud,Christine Mateus,Basil S. Cherpelis
Seminars in Oncology. 2012; 39(2): 227
[Pubmed] | [DOI]
8 Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: A case report and a review of the literature
Kuraishi, N., Nagai, Y., Hasegawa, M., Ishikawa, O.
Acta Dermato-Venereologica. 2010; 90(1): 73-76
[Pubmed]
9 Uncommon or Delayed Adverse Events Associated With Imatinib Treatment for Chronic Myeloid Leukemia
Rishard Salie, Richard T. Silver
Clinical Lymphoma Myeloma & Leukemia. 2010; 10(5): 331
[VIEW] | [DOI]
10 Lichenoid drug eruption related to imatinib: Report of a new case and review of the literature
Sendagorta, E., Herranz, P., Feito, M., Ramírez, P., Feltes, R., Floristán, U., Mariño-Enriquez, A., Casado, M.
Clinical and Experimental Dermatology. 2009; 34(7): e315-e316
[Pubmed]
11 A case of lichen planus associated to treatment with imatinib | [Un caso de liquen plano asociado a tratamiento con imatinib]
Martínez de Lagrán, Z., González-Hermosa, M.R., Blaya-Álvarez, B., Díaz-Pérez, J.L.
Medicina Clinica. 2009; 133(20): 805-806
[Pubmed]
12 Lichenoid drug eruption related to imatinib: report of a new case and review of the literature
E. Sendagorta,P. Herranz,M. Feito,P. Ramírez,R. Feltes,U. Floristán,A. Mariño-Enriquez,M. Casado
Clinical and Experimental Dermatology. 2009; 34(7): e315
[Pubmed] | [DOI]
13 Reacción liquenoide a imatinib
María Carmen Díaz-Sarrió,Gemma Martín-Ezquerra,Carles Barranco Sanz
Piel. 2008; 23(4): 169
[Pubmed] | [DOI]
14 Oral and cutaneous lichenoid reaction with nail changes secondary to imatinib: Report of a case and literature review
Wahiduzzaman, M., Pubalan, M.
Dermatology Online Journal. 2008; 14(12): Art 14
[Pubmed]
15 Lichenoid cutaneous reaction to imatinib | [Reacción liquenoide a imatinib]
Díaz-Sarrió, M.C., Martín-Ezquerra, G., Sanz, C.B.
Piel. 2008; 23(4): 169-171
[Pubmed]
16 Lichenoid drug eruption associated with imatinib mesylate: Two cases
Kiki, I., Atasoy, M., Gursan, N., Gundogdu, M., Erdem, F., Ozdemir, S.
European Journal of General Medicine. 2007; 4(1): 50-53
[Pubmed]
17 Cutaneous Lichenoid dermatitis associated with imatinib mesylate
Chan CYS, Browning J, Smith-Zagone MJ, Martinelli PT, Hsu S
Dermatology Online Journal. 2007; 13(2): Art No 29
[Pubmed]



 

Top
Print this article  Email this article
Previous article Next article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow